Clinical and biomarker characteristics of Huntington's Disease patients recently proposed for huntingtin-lowering clinical trial inclusion

被引：0
|
作者：
Parkin, G.
Thomas, E.
Snell, C.
Smirnova, A.
Hall, A.
Bohall, L.
Churchill, E.
Corey-Bloom, J.
机构：
来源：
MOVEMENT DISORDERS | 2022年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
649
引用
收藏
页码：S304 / S304
页数：1
相关论文
共 50 条
  • [21] Baseline lipid traits and the clinical characteristics and disease progression in Huntington's disease
    Zhang, S. R.
    Cheng, Y. F.
    Shang, H. F.
    MOVEMENT DISORDERS, 2024, 39 : S679 - S679
  • [22] Fifteen years of clinical trials in Huntington's disease: Too many clinical trial failures
    Travessa, A. M.
    Rodrigues, F. B.
    Mestre, T. A.
    Sampaio, C.
    Ferreira, J. J.
    MOVEMENT DISORDERS, 2016, 31 : S365 - S366
  • [23] Clinical and genetic characteristics of late-onset Huntington's disease
    Oosterloo, Mayke
    Bijlsma, Emilia
    van Kuijk, Sander
    Minkes, Floor
    Roos, Raymund
    de Die-Smulders, C. E. M.
    PARKINSONISM & RELATED DISORDERS, 2019, 61 : 101 - 105
  • [24] Clinical characterization of dystonia in adult patients with Huntington's disease
    van de Zande, N. A.
    Massey, T. H.
    McLauchlan, D.
    Roberts, A. Pryce
    Zutt, R.
    Wardle, M.
    Payne, G. C.
    Clenaghan, C.
    Tijssen, M. A. J.
    Rosser, A. E.
    Peall, K. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 (09) : 1140 - 1147
  • [25] Clinical features of Huntington's disease in 241 Chinese patients
    Guo, X. -Y.
    Zhang, S. -S.
    Zhao, B.
    Huang, R.
    Shang, H. -F.
    MOVEMENT DISORDERS, 2010, 25 (07) : S276 - S276
  • [26] Characteristics, pathophysiology and clinical management of weight loss in Huntington's disease
    Aziz, N. Ahmad
    Roos, Raymund A. C.
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2013, 3 (03) : 253 - 266
  • [27] Magnetic Resonance Imaging Striatal Volumes: A Biomarker for Clinical Trials in Huntington's Disease
    Aylward, Elizabeth H.
    MOVEMENT DISORDERS, 2014, 29 (11) : 1429 - 1433
  • [28] Neurofilament light protein: An emerging clinical and translational biofluid biomarker for Huntington's disease
    Byrne, L.
    Rodrigues, F.
    Johnson, E.
    Gregory, S.
    Kucharz, R. Soylu
    Bjorkqvist, M.
    Heslegrave, A.
    Blennow, K.
    Durr, A.
    Leavitt, B.
    Roos, R.
    Tabrizi, S.
    Zetterberg, H.
    Langbehn, D.
    Scahill, R.
    Wild, E.
    MOVEMENT DISORDERS, 2018, 33 : S377 - S378
  • [29] Motor Speech Phenotype of Huntington's Disease: A Clinical Biomarker in Premanifest and Early Phases
    Chan, Jess C. S.
    Stout, Julie C.
    Vogel, Adam P.
    NEUROTHERAPEUTICS, 2019, 16 (04) : 1385 - 1386
  • [30] Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial
    Langbehn, Douglas R.
    Fine, Elisabeth M.
    Meier, Andreas
    Hersch, Steven
    MOVEMENT DISORDERS, 2022, 37 (05) : 1040 - 1046
12345